{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:32Z","timestamp":1777692992550,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Racial and sex disparities in the incidence and outcomes of patients with intrahepatic cholangiocarcinoma (iCCA) exist, yet potential\u00a0genomic variations of iCCA based on race and sex that might be contributing to disparate outcomes\u00a0have not been well studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the American Association for Cancer Research\u00a0Project GENIE registry (version 15.0) were analyzed to assess genetic variations in iCCA. Adult patients (age &gt;18 years) with histologically confirmed iCCA who underwent next-generation sequencing were included in the analytic cohort. Racial and sex variations in genomic profiling of iCCA were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled 1068 patients from 19 centers (White, 71.9%; Black, 5.1%; Asian, 8.4%, other, 14.6%). The male-to-female ratio was 1:1. The majority of the patients had primary tumors (73.7%), whereas 23.0% had metastatic disease sequenced. While <jats:italic>IDH1<\/jats:italic> mutations occurred more frequently in White versus Black patients (20.8% vs. 5.6%; <jats:italic>p<\/jats:italic> = 0.021), <jats:italic>FGFR2<\/jats:italic> mutations tended to be more common among Black versus White populations (27.8% vs. 16.1%; <jats:italic>p<\/jats:italic> = 0.08). Males were more likely to have <jats:italic>TP53<\/jats:italic> mutations than females (24.3% vs. 18.2%, <jats:italic>p<\/jats:italic> = 0.016), whereas females more frequently had <jats:italic>IDH1<\/jats:italic> (23.3% vs 16.0 %), <jats:italic>FGFR2<\/jats:italic> (21.0% vs. 11.3%), and <jats:italic>BAP1<\/jats:italic> (23.4% vs. 14.5%) mutations than males (all <jats:italic>p<\/jats:italic> &lt; 0.05). Marked variations in the prevalence of other common genomic alterations in iCCA were noted across different races and sexes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Distinct genomic variations exist in iCCA across race and sex. Differences in mutational profiles of iCCA patients highlight the importance of including a diverse patient population in iCCA clinical trials as well as the importance of\u00a0recognizing different genetic drivers that may be targetable to treat\u00a0distinct patient cohorts.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-16141-8","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T18:02:43Z","timestamp":1725904963000},"page":"9071-9078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Racial and Sex Differences in Genomic Profiling of Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-9263","authenticated-orcid":false,"given":"Diamantis I.","family":"Tsilimigras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter","family":"Stecko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"7","key":"16141_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00432-010-0971-z","volume":"137","author":"AK Singal","year":"2011","unstructured":"Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma: frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071\u20138.","journal-title":"J Cancer Res Clin Oncol."},{"key":"16141_CR2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43:1777\u201387.","journal-title":"World J Surg."},{"key":"16141_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565\u201374.","journal-title":"JAMA Surg."},{"key":"16141_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, et al. NCCN guidelines(R) insights: biliary tract cancers, version 2.2023. J Natl Compr Cancer Netw. 2023;21:694\u2013704.","journal-title":"J Natl Compr Cancer Netw."},{"key":"16141_CR5","doi-asserted-by":"publisher","first-page":"1321683","DOI":"10.3389\/fonc.2024.1321683","volume":"14","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies. Front Oncol. 2024;14:1321683.","journal-title":"Front Oncol."},{"key":"16141_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med."},{"key":"16141_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol."},{"key":"16141_CR8","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24:4154\u201361.","journal-title":"Clin Cancer Res."},{"key":"16141_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","volume":"87","author":"L Verlingue","year":"2017","unstructured":"Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:122\u201330.","journal-title":"Eur J Cancer."},{"key":"16141_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5604\/01.3001.0012.0929","volume":"17","author":"SO Antwi","year":"2018","unstructured":"Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995\u20132014. Ann Hepatol. 2018;17:604\u201314.","journal-title":"Ann Hepatol."},{"key":"16141_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"Consortium APG","year":"2017","unstructured":"Consortium APG. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331.","journal-title":"Cancer Discov."},{"key":"16141_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00011","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00011.","journal-title":"JCO Precis Oncol."},{"key":"16141_CR13","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","DOI":"10.1126\/scisignal.2004088"},{"key":"16141_CR14","unstructured":"cBioPortal for Cancer Genomics. Retrieved 1 March 2024 at https:\/\/www.cbioportal.org\/."},{"key":"16141_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MOG.0b013e3283523c7e","volume":"28","author":"JB Andersen","year":"2012","unstructured":"Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28:266\u201372.","journal-title":"Curr Opin Gastroenterol."},{"key":"16141_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33205","volume":"4","author":"CM Aldrighetti","year":"2021","unstructured":"Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open. 2021;4:e2133205.","journal-title":"JAMA Netw Open."},{"key":"16141_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol."},{"key":"16141_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824\u201330.","journal-title":"JAMA Oncol."},{"key":"16141_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72\u20139.","journal-title":"Oncologist."},{"key":"16141_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344.","journal-title":"Nature."},{"key":"16141_CR21","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/onc.2012.315","volume":"32","author":"P Wang","year":"2013","unstructured":"Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091\u2013100.","journal-title":"Oncogene."},{"key":"16141_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264\u201379.","journal-title":"Cancer Discov."},{"key":"16141_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol."},{"key":"16141_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol."},{"key":"16141_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","volume":"157","author":"SL Zhou","year":"2022","unstructured":"Zhou SL, Xin HY, Sun RQ, et al. Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157:59\u201365.","journal-title":"JAMA Surg."},{"key":"16141_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:e115383.","journal-title":"PLoS One."},{"key":"16141_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25:744\u201350.","journal-title":"Nat Med."},{"key":"16141_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339.","journal-title":"N Engl J Med."},{"key":"16141_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6:803\u201315.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16141-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:05:43Z","timestamp":1731071143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16141"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16141-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}